Selected stock price target news of the day - January 8th, 2025

By: Matthew Otto

Personalis Reports Preliminary Full-Year and Q4 2024 Results

Personalis has announced preliminary revenue and cash balance details for the year ended December 31, 2024, reporting full-year revenue of approximately $84.6 million. It is a 15% increase compared to $73.5 million in 2023. This surpass its prior guidance range of $83.0 to $84.0 million.

Revenue from pharma tests, enterprise sales, and other customers grew 20% year-over-year to $77.2 million, despite a 20% decline in revenue from Natera to $25.4 million. Meanwhile, revenue from the VA Million Veterans Program (VA MVP) decreased 21% to $7.4 million.

In Q4 2024, Personalis generated $16.8 million in revenue, down 15% year-over-year, driven by anticipated declines in revenue from Natera and the VA MVP. However, molecular test volume surged 52%, with 1,441 tests delivered in Q4 compared to 945 in Q3.

Analyst Ratings Highlight Growth Potential Amid Personalis’ Revenue Gains

HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a Buy rating and a price target of $11.
Needham analyst Mike Matson kept a Buy rating and a $7.25 price target.

Which Analyst has the best track record to show on PSNL?

Analyst Mike Matson (NEEDHAM) currently has the highest performing score on PSNL with 6/14 (42.86%) price target fulfillment ratio. His price targets carry an average of $1.99 (37.83%) potential upside. Personalis stock price reaches these price targets on average within 98 days.

Stoke Therapeutics Advances Phase 3 Trial for Dravet Syndrome Therapy

Stoke Therapeutics announced global regulatory alignment with the FDA, EMA, and PMDA for its pivotal Phase 3 EMPEROR study evaluating zorevunersen as a disease-modifying therapy for Dravet syndrome.

The study will enroll approximately 150 patients aged 2 to under 18 years, representing a critical step in addressing the estimated 35,000 individuals living with Dravet syndrome across the US, EU, UK, and Japan. Dravet syndrome, a rare condition affecting approximately 1 in 15,600 births globally, is characterized by frequent seizures and developmental challenges.

The EMPEROR study will evaluate a dosing regimen of two 70 mg loading doses followed by two 45 mg maintenance doses over 52 weeks. Its primary endpoint will measure percentage reductions in major motor seizure frequency, while secondary endpoints will assess cognitive and behavioral improvements using the Vineland-3 scale.

Zorevunersen has shown promising results in earlier studies, with an 87% median reduction in convulsive seizure frequency observed eight months after treatment began, and sustained cognitive and behavioral improvements recorded over two years. With over 600 doses administered to date, zorevunersen has been well tolerated, and the FDA’s Breakthrough Therapy Designation highlights its potential to address the unmet needs of Dravet syndrome patients.

Analysts Reaffirm Confidence Amid Phase 3 Trial Progress

HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating along with a $35 price target.
Needham analyst Joseph Stringer retained a Buy rating and set a $22 price target.
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating.

Which Analyst has the best track record to show on STOK?

Analyst Joseph Stringer (NEEDHAM) currently has the highest performing score on STOK with 5/17 (29.41%) price target fulfillment ratio. His price targets carry an average of $8.75 (66.04%) potential upside. Stoke Therapeutics stock price reaches these price targets on average within 48 days.

Adobe’s Analytics Reveal Record-Breaking 2024 Holiday Shopping Trends

Adobe reported record-breaking online shopping activity during the 2024 holiday season, as consumers spent $241.4 billion online from November 1 to December 31—a year-over-year (YoY) increase of 8.7%. Data from Adobe Analytics, which tracks over 1 trillion visits to U.S. retail sites and 100 million SKUs across 18 categories, highlighted the growing dominance of mobile shopping.

Smartphones accounted for 54.5% of online transactions, up from 51.1% in 2023, with Christmas Day hitting a peak of 65%. Cyber Week was a standout period, generating $41.1 billion in sales, with Cyber Monday alone contributing $13.3 billion.

Key categories such as electronics – up 8.8% YoY with $55.3 billion, apparel – up 9.9% YoY with $45.6 billion, and furniture/home goods – up 6.8% YoY with $29.2 billion, led the season’s growth, while grocery and cosmetics posted at 12.9% and 12.2%, respectively.

Discounts in electronics peaked at 30.1%, while toys and apparel saw reductions of 28% and 23.2%, respectively, driving an additional $2.25 billion in online sales. Generative AI-powered chatbots emerged as key shopping assistants, with traffic to retail sites through these tools surging by 1,300% YoY, including a 1,950% spike on Cyber Monday.

Furthermore, “Buy Now, Pay Later” (BNPL) services gained traction, contributing $18.2 billion to holiday sales, with 79.1% of BNPL transactions made via smartphones. Adobe’s insights revealed that for every 1% price decrease, demand increased by 1.029%.

Analyst Ratings and Price Target Adjustments Following Holiday Season Report

Deutsche Bank analyst Brad Zelnick downgraded from Buy to Hold and the price target to $475 from $600.
Wells Fargo analyst Michael Turrin yesterday maintained an Overweight rating but adjusted the price target down from $700 to $640.

Which Analyst has the best track record to show on ADBE?

Analyst Karl Keirstead (UBS) currently has the highest performing score on ADBE with 10/14 (71.43%) price target fulfillment ratio. His price targets carry an average of $46.98 (10.98%) potential upside. Adobe stock price reaches these price targets on average within 112 days.